Abstract
a s ite ho ste d b y M ed kn ow P ub lic ati on s therapy in the CD4 stratum between 200-350 cells/ organization and UNAIDS are aiming for “universal mm in an asymptomatic patient is a controversial access to ART for all by 2010”. The dramatic decline issue. ART should probably be started within this range in annual AIDS-related mortality has largely been depending on the symptoms, viral load, CD4 slope, attributed to the use of highly active antiretroviral patient preference, and associated co-morbidities. therapy (HAART). Several effective antiretroviral agents are available and many more are in the pipeline The pretreatment evaluation should include a [Table 1]. However, injudicious use of ART may be complete history and physical examination, fundus harmful to patients as well as society at large. It is examination, complete blood count, biochemistry therefore essential that the treating physician has a profile, lipid profile, CD4/CD8 T cell count/ratio, clear set of goals to guide him/her. This includes plasma HIV-1 RNA measurement (viral load) and achieving not just maximal viral load suppression or supplementary tests including VDRL, Mantoux test, qualitative and quantitative immune reconstitution chest X-ray and serology for hepatitis C and B. In .m ed kn ow .co ).
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call